PURPOSE OF REVIEW: To present the pharmacologic and biologic profile of levosimendan and discuss potential indications in the treatment of sepsis and septic shock, with a special focus on myocardial and pulmonary dysfunction. RECENT FINDINGS: In animal models of endotoxic shock, levosimendan improved both left ventricular systolic and diastolic dysfunction, as well as ventriculovascular coupling. In addition, positive effects have been reported on right ventricular performance and pulmonary circulation. Two randomized, controlled trials in patients with septic shock revealed levosimendan provided consistent beneficial effects on cardiopulmonary performance, global oxygen transport, splanchnic perfusion and renal function. These effects have been reported as superior to placebo and the classic inotropic agent dobutamine. Due to its vasodilatory effects, combination with vasoconstrictor agents may be crucial in the presence of arterial hypotension. SUMMARY: There is increasing evidence that levosimendan exerts beneficial effects in the treatment of sepsis-induced myocardial and pulmonary dysfunction. Future large-scale multicenter clinical trials are now needed to clarify whether levosimendan improves the overall outcome of patients with sepsis and septic shock.
PURPOSE OF REVIEW: To present the pharmacologic and biologic profile of levosimendan and discuss potential indications in the treatment of sepsis and septic shock, with a special focus on myocardial and pulmonary dysfunction. RECENT FINDINGS: In animal models of endotoxic shock, levosimendan improved both left ventricular systolic and diastolic dysfunction, as well as ventriculovascular coupling. In addition, positive effects have been reported on right ventricular performance and pulmonary circulation. Two randomized, controlled trials in patients with septic shock revealed levosimendan provided consistent beneficial effects on cardiopulmonary performance, global oxygen transport, splanchnic perfusion and renal function. These effects have been reported as superior to placebo and the classic inotropic agent dobutamine. Due to its vasodilatory effects, combination with vasoconstrictor agents may be crucial in the presence of arterial hypotension. SUMMARY: There is increasing evidence that levosimendan exerts beneficial effects in the treatment of sepsis-induced myocardial and pulmonary dysfunction. Future large-scale multicenter clinical trials are now needed to clarify whether levosimendan improves the overall outcome of patients with sepsis and septic shock.
Authors: Elmir Omerovic; Truls Råmunddal; Per Albertsson; Mikael Holmberg; Per Hallgren; Jan Boren; Lars Grip; Göran Matejka Journal: Vasc Health Risk Manag Date: 2010-09-07
Authors: Andrea Morelli; Abele Donati; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Giovanni Landoni; Paolo Pelaia; Paolo Pietropaoli; Hugo Van Aken; Jean-Louis Teboul; Can Ince; Martin Westphal Journal: Crit Care Date: 2010-12-23 Impact factor: 9.097
Authors: Antoine Guillon; Sebastien Preau; Jérôme Aboab; Eric Azabou; Boris Jung; Stein Silva; Julien Textoris; Fabrice Uhel; Dominique Vodovar; Lara Zafrani; Nicolas de Prost; Peter Radermacher Journal: Ann Intensive Care Date: 2019-06-10 Impact factor: 6.925
Authors: Robert M L'E Orme; Gavin D Perkins; Daniel F McAuley; Kathleen D Liu; Alexina J Mason; Andrea Morelli; Mervyn Singer; Deborah Ashby; Anthony C Gordon Journal: Trials Date: 2014-06-02 Impact factor: 2.279